AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$FENC

Sayad Pierre Sargis sold $146K of FENC

Sayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $12.18 ($0.15M total) on 2026-08-31.

Original reporting
SEC EDGAR · Sayad Pierre Sargis
Published Sep 1, 2026, 12:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 12:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FENC
Bearish
medium confidence
Mentioned
$FENC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FENCBearishLow
01

Why it matters

The sale represents a small reduction in insider ownership, unlikely to move the stock significantly.

02

Market read

Minor insider sell; limited trading relevance.

03

What to watch

Potential upcoming clinical data or corporate actions not disclosed.

Relevance 4/10Novelty 8/10Timing: post-market filing on 2026-08-31

Background

Form 4 filings disclose insider transactions; investors monitor CMO sales for signals.

Company-level read

Ticker impact

$FENCBearishMedium confidence
Context

Chief Medical Officer Sayad Pierre Sargis sold 12,000 shares for $146,160 on 2026-08-31 via a Form 4 filing.

Expected impact

Potential slight dip in short term as market digests insider sell.

Evidence & confidence

Sale size is modest relative to holdings, but CMO insider activity is closely watched.

Market effects

Sector

Minimal impact on biotech sector; insider sales are routine.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not imply negative outlook.

Key entities

  • Company
    Fennec Pharmaceuticals Inc.

    Biotech firm developing oncology therapies.

  • Person
    Sayad Pierre Sargis

    Chief Medical Officer of Fennec Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FENC insider trading history →

Related articles

SEP 17
$FENCMedAI 8/10

FENNEC PHARMACEUTICALS INC. (FENC): Other Events

FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK ® in Japan AT SIOP 2026 ​ ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ

SEC EDGAR 8-K2 min
AUG 13
$FENCMed

Adherex Technologies Q2 Earnings Call Highlights

Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.

yahoo.com6 min